| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 920.71M | 851.95M | 752.84M | 585.88M | 464.68M | 358.43M |
| Gross Profit | 561.55M | 537.66M | 438.07M | 332.49M | 275.75M | 234.41M |
| EBITDA | 277.22M | 255.43M | 225.88M | 159.99M | 168.81M | 143.23M |
| Net Income | 189.90M | 191.91M | 156.46M | 131.71M | 142.96M | 121.35M |
Balance Sheet | ||||||
| Total Assets | 2.88B | 2.26B | 2.03B | 1.83B | 1.62B | 1.42B |
| Cash, Cash Equivalents and Short-Term Investments | 505.05M | 554.51M | 434.40M | 528.27M | 640.55M | 941.59M |
| Total Debt | 569.86M | 243.69M | 94.78M | 48.83M | 13.40M | 1.73M |
| Total Liabilities | 917.75M | 473.39M | 351.25M | 273.23M | 183.63M | 95.04M |
| Stockholders Equity | 1.88B | 1.77B | 1.65B | 1.51B | 1.40B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 146.08M | 59.80M | -53.05M | -62.75M | -205.07M | 7.92M |
| Operating Cash Flow | 243.39M | 225.54M | 178.15M | 180.46M | 72.76M | 95.71M |
| Investing Cash Flow | -455.54M | -187.31M | -283.81M | -316.18M | -268.08M | -221.87M |
| Financing Cash Flow | 360.65M | 56.97M | 8.06M | 9.72M | -31.07M | -27.95M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.90B | 12.32 | 3.76% | 7.46% | 21.39% | -0.57% | |
74 Outperform | HK$4.93B | 10.39 | 17.42% | 3.65% | 6.87% | 18.37% | |
72 Outperform | HK$26.13B | 45.22 | 24.57% | 0.63% | 13.58% | 24.59% | |
70 Neutral | HK$5.46B | 26.37 | 10.31% | ― | 14.06% | 3.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$468.92M | -15.00 | ― | ― | -8.46% | 45.13% |
Shanghai Kindly Medical Instruments Co., Ltd. has announced its intention to implement full circulation of its H shares. The company has submitted a filing to the China Securities Regulatory Commission (CSRC) for the conversion of 71,786,608 domestic shares into H shares, which will then be listed and traded on the Hong Kong Stock Exchange. This move is part of the company’s strategy to enhance its market presence and liquidity. The conversion and listing are subject to regulatory approvals and compliance with applicable laws, and further announcements will be made as the process progresses.
The most recent analyst rating on (HK:1501) stock is a Hold with a HK$34.00 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.
Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Subscription Agreement with Broncus Holding Corporation. The agreement involves Shanghai Kindly subscribing to 91,093,613 new shares of Broncus at a price of HK$3.11 per share, totaling approximately HK$283.3 million. This transaction will result in Shanghai Kindly holding about 17.24% of Broncus’s issued shares. However, the financial results of Broncus will not be consolidated into Shanghai Kindly’s accounts. The transaction is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement due to the applicable percentage ratios.
The most recent analyst rating on (HK:1501) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.